{"nctId":"NCT00687804","briefTitle":"A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study","startDateStruct":{"date":"2008-05"},"conditions":["Diabetic Macular Edema"],"count":345,"armGroups":[{"label":"Ranibizumab 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab","Procedure: Laser","Procedure: Sham laser"]},{"label":"Ranibizumab 0.5 mg + laser","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab","Procedure: Laser"]},{"label":"Laser","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ranibizumab","Procedure: Laser","Drug: Sham to ranibizumab"]}],"interventions":[{"name":"Ranibizumab","otherNames":[]},{"name":"Laser","otherNames":[]},{"name":"Sham laser","otherNames":[]},{"name":"Sham to ranibizumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Visual acuity impairment\n* Diabetic macular edema in at least one eye\n* Type 1 or type 2 diabetes mellitus\n* Medication for the diabetes treatment must be stable for the last 3 months\n\nExclusion Criteria:\n\n* Patients with uncontrolled systemic or ocular diseases\n* Laser photocoagulation in the study eye for the last 3 months\n* Any history of any intraocular surgery in the study eye within the past 3 months\n* Blood pressure \\> 160/100 mmHg\n\nExtension Inclusion Criteria:\n\n-Completion of the Core Study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Core Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12","description":"Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":"10.07"},{"groupId":"OG001","value":"63.4","spread":"9.99"},{"groupId":"OG002","value":"62.6","spread":"11.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":"10.53"},{"groupId":"OG001","value":"69.2","spread":"11.44"},{"groupId":"OG002","value":"63.4","spread":"12.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"6.43"},{"groupId":"OG001","value":"5.9","spread":"7.92"},{"groupId":"OG002","value":"0.8","spread":"8.56"}]}]}]},{"type":"SECONDARY","title":"Core Study: Categorized Change in Visual Acuity (Letters) of the Study Eye From Baseline at Month 12","description":"Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Core Study: Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time","description":"Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.49"},{"groupId":"OG001","value":"3.1","spread":"0.56"},{"groupId":"OG002","value":"0.5","spread":"0.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"0.64"},{"groupId":"OG001","value":"4.9","spread":"0.56"},{"groupId":"OG002","value":"0.4","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"0.65"},{"groupId":"OG001","value":"5.8","spread":"0.65"},{"groupId":"OG002","value":"-0.5","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"0.68"},{"groupId":"OG001","value":"5.4","spread":"0.69"},{"groupId":"OG002","value":"0.5","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"0.68"},{"groupId":"OG001","value":"5.7","spread":"0.76"},{"groupId":"OG002","value":"0.9","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"0.68"},{"groupId":"OG001","value":"6.2","spread":"0.78"},{"groupId":"OG002","value":"0.9","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"0.72"},{"groupId":"OG001","value":"6.5","spread":"0.84"},{"groupId":"OG002","value":"1.1","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"0.75"},{"groupId":"OG001","value":"6.4","spread":"1.06"},{"groupId":"OG002","value":"1.3","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"0.76"},{"groupId":"OG001","value":"6.8","spread":"1.05"},{"groupId":"OG002","value":"1.4","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"0.77"},{"groupId":"OG001","value":"6.4","spread":"1.04"},{"groupId":"OG002","value":"0.8","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"0.79"},{"groupId":"OG001","value":"6.8","spread":"1.10"},{"groupId":"OG002","value":"1.4","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"0.77"},{"groupId":"OG001","value":"6.4","spread":"1.08"},{"groupId":"OG002","value":"0.9","spread":"1.09"}]}]}]},{"type":"SECONDARY","title":"Core Study: Mean Change From Baseline at Month 12 in Central Retinal Thickness of the Study Eye","description":"Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"427.1","spread":"118.42"},{"groupId":"OG001","value":"416.4","spread":"119.91"},{"groupId":"OG002","value":"412.4","spread":"124.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"308.4","spread":"112.26"},{"groupId":"OG001","value":"288.2","spread":"90.11"},{"groupId":"OG002","value":"351.1","spread":"139.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-118.7","spread":"115.07"},{"groupId":"OG001","value":"-128.3","spread":"114.34"},{"groupId":"OG002","value":"-61.3","spread":"132.29"}]}]}]},{"type":"SECONDARY","title":"Core Study: Mean Change From Baseline in Patient-reported Visual Functioning","description":"The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":"16.91"},{"groupId":"OG001","value":"74.1","spread":"18.06"},{"groupId":"OG002","value":"73.5","spread":"18.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":"19.19"},{"groupId":"OG001","value":"79.5","spread":"17.29"},{"groupId":"OG002","value":"74.1","spread":"18.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"12.97"},{"groupId":"OG001","value":"5.4","spread":"11.14"},{"groupId":"OG002","value":"0.6","spread":"12.56"}]}]}]},{"type":"PRIMARY","title":"Extension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 24 Month Extension Study","description":"Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant.\n\nAdditional information about adverse events can be found in the Adverse Event section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.6","spread":null},{"groupId":"OG001","value":"56.6","spread":null},{"groupId":"OG002","value":"52.5","spread":null},{"groupId":"OG003","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"1.7","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 36 Months of the Core and Extension Studies","description":"Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant.\n\nAdditional information about adverse events can be found in the Adverse Event section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.3","spread":null},{"groupId":"OG001","value":"67.5","spread":null},{"groupId":"OG002","value":"64.4","spread":null},{"groupId":"OG003","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"5.1","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 36 Months of the Core and Extension Studies","description":"Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant.\n\nAdditional information about Adverse Events can be found in the Adverse Event section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.1","spread":null},{"groupId":"OG001","value":"81.9","spread":null},{"groupId":"OG002","value":"84.7","spread":null},{"groupId":"OG003","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null},{"groupId":"OG001","value":"37.3","spread":null},{"groupId":"OG002","value":"42.4","spread":null},{"groupId":"OG003","value":"13.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Extension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 24 Month Extension Study","description":"Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant.\n\nAdditional information about adverse events can be found in the Adverse Event section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":null},{"groupId":"OG001","value":"73.5","spread":null},{"groupId":"OG002","value":"71.2","spread":null},{"groupId":"OG003","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"30.1","spread":null},{"groupId":"OG002","value":"37.3","spread":null},{"groupId":"OG003","value":"13.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Study: Mean Change From Extension Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36","description":"Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"9.10"},{"groupId":"OG001","value":"-0.5","spread":"9.19"},{"groupId":"OG002","value":"3.7","spread":"6.88"}]}]}]},{"type":"SECONDARY","title":"Extension Study: Mean Change From Core Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36","description":"Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"10.09"},{"groupId":"OG001","value":"6.7","spread":"9.59"},{"groupId":"OG002","value":"6.0","spread":"9.35"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":115},"commonTop":["Nasopharyngitis","Diabetic retinal oedema (Fellow eye)","Eye pain (Study eye)","Cataract (Study eye)","Hypertension"]}}}